Table 2.
NY-ESO-1 adoptive T cell therapy modalities currently in clinical trial.
| NCT number | Other IDs | Interventions | Conditions | Status |
|---|---|---|---|---|
| NCT02366546 | 1301-01 | TBI-1301 | Advanced solid tumors | Recruiting |
| NCT02869217 | 1301-02 | TBI-1301 | Advanced solid tumors | Recruiting |
| NCT03250325 | 1301-03 | TBI-1301 | Synovial sarcoma | Recruiting |
| NCT03047811 | NY-TCR WXH 2016 | NY-ESO-1 TCR-T cells | Advanced solid tumors | Recruiting |
| NCT02457650 | 201504002 | NY-ESO-1 TCR-T cells | Metastatic solid tumors | Recruiting |
| NCT01795976 | ATTACK-OG|12_DOG14_22 | NY-ESO-1 TCR-T cells | Esophageal cancer | Active, not recruiting |
| NCT03093350 | H-39209 TACTIC | Multi TAA T cells (NY-ESO-1, MAGEA4, PRAME, survivin and SSX2) | Breast cancer | Not yet recruiting |
| NCT03192462 | H-40378 TACTOPS | Multi TAA T cells (NY-ESO-1, MAGEA4, PRAME, survivin and SSX2) | Pancreatic cancer | Not yet recruiting |
| NCT02239861 | H-35425, TACTASOM | Multi TAA T cells (NY-ESO-1, MAGEA4, PRAME, survivin and SSX2) | Rhabdomyosarcoma | Recruiting |
| NCT02291848 | H-35626, TACTAM | Multi TAA T cells (NY-ESO-1, MAGEA4, PRAME, survivin and SSX2) | Multiple myeloma | Recruiting |
| NCT02494167 | H-36346 ADSPAM | Multi TAA T cells (WT1, NY-ESO-1, PRAME, and survivin) | Acute myeloid leukemia, myelodysplastic syndrome | Recruiting |
| NCT03175705 | Beijing Youan Ethics[2017]06 | Multi TAA T cells (GPC-3, NY-ESO-1, AFP) | Hepatocellular carcinoma | Recruiting |
| NCT02774291 | 2015-5254|NCI-2015-01781|P30CA013330 | Murine NY-ESO-1 TCR-T cells | Metastatic solid tumors | Not yet recruiting |
| NCT01967823 | 130214|13-C-0214 | Murine NY-ESO-1 TCR-T cells | Metastatic solid tumors | Recruiting |
| NCT01567891 | ADP-0011-001|230612 | NY-ESO-1c259-T cells | Ovarian cancer | Recruiting |
| NCT01350401 | ADP 01611 | NY-ESO-1c259-T cells | Metastatic melanoma | Active, not recruiting |
| NCT01343043 | ADP 04511 | NY-ESO-1c259-T cells | Synovial sarcoma | Recruiting |
| NCT02992743 | ADP-0011-007 | NY-ESO-1c259-T cells | Advanced myxoid, round cell liposarcoma | Recruiting |
| NCT01892293 | ADP-0011-002 | NY-ESO-1c259-T cells | Multiple myeloma | Active, not recruiting |
| NCT02588612 | ADP-0011-004 | NY-ESO-1c259-T cells | Non-small-cell lung cancer | Recruiting |
| NCT01352286 | ADP 01411 | NY-ESO-1c259-T cells|stem cell transplantation | Multiple myeloma | Active, not recruiting |
| NCT03029273 | 2016-63 | TAEST16001 | Recurrent non-small cell lung cancer | Recruiting |
| NCT03159585 | TS20161229 | TAEST16001 | solid tumors | Recruiting |
TAA, tumor-associated antigen; TAEST16001, TCR affinity enhancing specific T cell therapy with autologous T cells transduced with affinity-enhanced NY-ESO-1 TCR; TBI-1301, NY-ESO-1 specific TCR-transduced T cells; TCR, T cell receptor.